should be over $15 already
ovarian, is 60.000 patients of which 40.000 in EU and they will get approval
smldc, is biliions as well as tubulysin, inflamm, and merch which will pay for dev. of 4 new threatments
hard to predict a stock price though seen manipulation, and rest of osmldc and part of phase 3 proceed ovarian, and too much cash